Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Article

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer

Article

Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential use in the adjuvant setting.

[powerpress]

Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"

Article

Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?

[powerpress]